Welcome to our dedicated page for PERRIGO Co plc SEC filings (Ticker: PRGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Perrigo Company plc filings document a consumer health issuer organized under Irish law, with disclosures covering operating results, non-GAAP measures, segment reporting, capital structure, governance, and material corporate events. Recent 8-K filings report quarterly earnings from continuing operations, the company's transition to product-category segments, and the completed sale of its Dermacosmetics branded business.
The filing record also covers Perrigo's ordinary shares, senior notes, revolving credit facility, and term loan arrangements, including amendments to credit agreements. Proxy and annual meeting materials document board matters, shareholder voting results, executive compensation, and the shareholder-approved 2026 Long-Term Incentive Plan.
T. Rowe Price Associates, Inc. reports beneficial ownership of 14,016,148 shares of Perrigo Co plc common stock, representing 10.2% of the class. The filing states sole voting power for 13,658,349 shares and sole dispositive power for 13,707,794.
T. Rowe Price Associates, Inc. amends its Schedule 13G/A to report ownership in Perrigo Co plc common stock. The filing states 13,376,708 shares beneficially owned, representing 9.7% of the class. It shows sole voting power of 13,327,263 and sole dispositive power of 13,376,708. The filing also identifies T. Rowe Price Mid‑Cap Value Fund with 7,498,410 shares (5.4%). The filing is signed by a T. Rowe Price Vice President.
Perrigo Company plc reported a sharp first‑quarter loss driven by large non‑cash impairments and restructuring costs. Net sales were $969.2 million, down from $1,043.9 million a year earlier, as Self Care, Specialty Care and All Other all declined modestly while Infant Formula was roughly flat.
The company recorded $330.8 million of goodwill impairments tied to Women’s Health, Infant Formula and Oral Care reporting units, plus $75.1 million of restructuring charges, turning operating income of $46.9 million last year into an operating loss of $372.3 million. Net loss from continuing and discontinued operations widened to $398.6 million, or $2.87 per diluted share, compared with a $6.4 million loss, or $0.05 per share, in the prior‑year period.
Cash used in operating activities was $113.6 million, and cash and cash equivalents fell to $357.2 million from $531.6 million at year‑end 2025. Total borrowings were $3,632.5 million, including $970.0 million of term loans and $2,262.2 million of notes and bonds. Perrigo also completed an amended credit agreement, drew $427.6 million on its revolver to repay Term Loan A, and completed the sale of its Dermacosmetics business after quarter‑end for up to €332.6 million in consideration.
Perrigo Company plc reported a large first‑quarter 2026 loss driven by a non‑cash goodwill impairment but kept its full‑year outlook. All In net sales from continuing operations fell to $969.2 million, down 7.2% year over year, with Core net sales down 8.3% as weaker cough, cold and other categories offset share gains.
Reported gross margin declined to 33.6% and reported operating margin dropped to (38.4)% after a $330.8 million goodwill impairment and higher restructuring charges. Reported diluted EPS from continuing operations was $(2.81), while All In adjusted diluted EPS was $0.43, down from $0.60. Specialty Care grew net sales 4.0% with stronger Women’s Health brands such as Opill and ellaOne, while Self Care net sales fell 11.5%.
After quarter end, Perrigo completed the sale of its Dermacosmetics business, receiving about €305.6 million in upfront cash expected to support debt reduction. Management reaffirmed 2026 guidance, including All In adjusted EPS of $2.00–$2.30 and Core adjusted EPS of $2.25–$2.55, and continues to highlight second‑half improvement despite current category and macro headwinds.
Perrigo Company plc held its 2026 Annual General Meeting of Shareholders on April 30, 2026. Shareholders approved the new 2026 Long-Term Incentive Plan, which became effective immediately and replaces the company’s 2019 long-term incentive plan.
All listed director nominees were elected with strong majorities; for example, Bradley A. Alford received 105,969,898 votes for and 1,290,063 against. Shareholders also voted on additional proposals that received substantial levels of support, with several items drawing more than 110 million votes in favor and limited opposition or abstentions.
Perrigo Company plc has completed the sale of its branded Dermacosmetics business to Karo Healthcare for total consideration of up to €332.6 million. The deal includes €305.6 million in upfront cash, with €5.6 million from net working capital adjustments, and up to €27.0 million of contingent consideration tied to net sales milestones over three years. In calendar 2025, the Dermacosmetics business generated about €120 million of net sales and around 5% of Perrigo’s adjusted operating income, so the divestiture is meaningful but not company‑defining. Perrigo expects to use the net proceeds primarily to reduce debt, which it believes will improve financial flexibility and strengthen its balance sheet.
For 2025, Perrigo reported consolidated continuing net sales of $4,253.1 million and a reported operating loss of $1,122.2 million, driven largely by $1.3 billion of goodwill impairment and other charges. After adjustments for amortization, restructuring, litigation, impairments and other items, adjusted operating income was $622.3 million, or 14.6% of net sales, equivalent to €551.4 million using a 0.8860 EUR/USD exchange rate.
Perrigo Co PLC — Vanguard Portfolio Management reported beneficial ownership of 8,254,465 shares of Perrigo common stock, representing 5.99% of the class as of 03/31/2026. The filing shows sole dispositive power over 8,254,465 shares and sole voting power for 112,546 shares. The Schedule 13G was signed on 04/28/2026.
Perrigo Co PLC reports a 5.27% passive stake held by Vanguard Capital Management. Vanguard Capital Management beneficially owns 7,260,072 shares of Perrigo common stock (CUSIP G97822103) as reported on 03/31/2026. The filing shows sole dispositive power over 7,260,072 shares and sole voting power for 1,050,535 shares. The Schedule 13G identifies Vanguard funds and affiliated advisory units as holders; signature dated 04/28/2026.
Perrigo Company plc updated its financial reporting to three product-based segments—Self Care, Specialty Care, and Infant Formula—and recast prior periods accordingly. For the year ended December 31, 2025, consolidated net sales were $4,253.1 million, compared with $4,373.4 million in 2024. Segment adjusted operating income for 2025 was $622.3 million, while reported operating income showed a loss of $1,122.2 million after recognizing a $1.3 billion goodwill impairment and a $33.6 million impairment on an equity method investment. The company also recorded restructuring, unusual litigation, and other adjustments, and continues to emphasize non‑GAAP measures such as adjusted operating income to evaluate performance. Recast segment data and non‑GAAP reconciliations for 2024–2025 are provided to help comparability under the new structure.
Perrigo Co PLC: Dimensional Fund Advisors filed Amendment No. 1 to a Schedule 13G/A reporting beneficial ownership of 6,567,616 shares of Common Stock, representing 4.8% of the class. The filing states Dimensional has 6,451,767 shares of sole voting power and 6,567,616 shares of sole dispositive power. The filing notes the shares are owned by various Funds managed or advised by Dimensional and that Dimensional disclaims beneficial ownership.